Histone deacetylase 6 selective inhibitors for the treatment of cisplatin-induced peripheral neuropathy
Disclosed are methods for treating cisplatin-induced peripheral neuropathy in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a histone deacetylase 6 selective inhibitor.
1. A method for restoring a loss of intra-epidermal nerve fiber (IENF) in a subject, comprising administering to the subject an effective amount of a histone deacetylase 6 selective inhibitor;
wherein the loss of intra-epidermal nerve fiber is the result of administering cisplatin to the subject.
2. The method of claim 1 , wherein the administration of the histone deacetylase 6 selective inhibitor to the subject occurs during or after administering cisplatin.
3. The method of claim 1 , wherein the histone deacetylase 6 selective inhibitor is compound 001:
or a pharmaceutically acceptable salt thereof.
4. The method of claim 1 , wherein the histone deacetylase 6 selective inhibitor is co-administered with cisplatin.
5. The method of claim 1 , wherein the histone deacetylase 6 selective inhibitor is administered before administering cisplatin.